PNB Vesper, a Kochi-based life sciences company, on September 11 said it has received approval from the Drugs Controller General of India (DCGI) to conduct the Phase 2b clinical trial of their propriety drug PNB-001 (GPP-Baladol) on COVID-19 patients.
The company has filed the clinical trial application with the DCGI for the Phase 2 clinical trials, and the study will be completed in 60 days. The study will be conducted on 40 Covid-19 positive patients, who are moderate patients on oxygen support, at BMJ Medical College, Pune.
The effect of PNB-001 will be compared with dexamethasone, currently the most popular medicine in Covid-19 treatment in the world.